Cardurion Pharmaceuticals Completes Enrollment in Phase 2 CYCLE Trials Evaluating CRD‑750, a Novel PDE9 inhibitor, in Heart Failure
Burlington, MA, August 6, 2025 – Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of patients with cardiovascular diseases, today announced that it has completed enrollment in two global, multi-center, Phase 2 clinical trials assessing the safety and efficacy of CRD-750 in both types of chronic heart failure (HFrEF and […]
Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer
Burlington, Mass., March 20, 2025 – Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and […]
Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer
Burlington, Mass., January 8, 2025 – Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently led corporate, […]
Cardurion Pharmaceuticals Selected as an Endpoints 11 Most Promising Biotech Company
Burlington, Mass., September 27, 2024 – Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced that it has been named as one of the Endpoints 11 most promising private biotechnology companies of 2024. Cardurion has been chosen by the Endpoints News editorial team because of […]
Cardurion Pharmaceuticals Appoints Ron Renaud to Board of Directors
Veteran biotech industry leader joins as company enters next stage of growth BURLINGTON, Mass. – September 26, 2024 –Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Ron Renaud as a member of the company’s Board of Directors. Mr. […]
Cardurion Pharmaceuticals Announces $260 Million Series B Financing to Advance Its Pipeline of Innovative Medicines for Cardiovascular Diseases
Company’s first-in-class PDE9 inhibitor for heart failure and first-in-class CaMKII inhibitor move into later-stage clinical trials in cardiovascular diseases Financing enables further expansion of pipeline and acceleration of capabilities as a cardiovascular drug innovator BURLINGTON, Mass. – July 17, 2024 – Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment […]
Cardurion Pharmaceuticals Presents Positive Clinical Results from CARDINAL‑HF Phase 2a Clinical Trial of PDE9 Inhibitor in Patients With Heart Failure
Burlington, Mass. – May 11, 2024 – Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced the presentation of positive clinical data from CARDINAL‑HF, the first Phase 2 proof-of-concept clinical trial of a phosphodiesterase-9(PDE9) inhibitor in patients with heart failure. These data were presented today at […]
Cardurion Pharmaceuticals to Provide Update on CaMKII Inhibitor Program at the American Heart Association’s Scientific Sessions 2023
Next Generation Cardiovascular Biotech to Present non-clinical Data on Two of its Novel, Potent, and Highly Selective CaMKII Inhibitors First Company to Study a CaMKII Inhibitor in a Clinical Trial BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the […]
Cardurion Pharmaceuticals Welcomes Emma Reeve as Independent Board Director and Audit Chair
Accomplished CFO and Board Leader to Provide Independent Leadership to Deliver on Company’s Growth Strategy BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Emma Reeve as an independent board […]
Cardurion Pharmaceuticals Further Bolsters Leadership Team with Appointment of Stephen Migausky as General Counsel
Experienced Life Sciences Executive Brings 15 Years of Legal, Corporate Strategy, and Business Development Experience BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Stephen Migausky as Senior Vice President […]